Maria R. Baer - Concepedia

Author

Maria R. Baer

University of Maryland, Baltimore ORCID

Also Known As

Lionel Ades, M Baer, M R Baer, M. + BAER, M. Baer, M. R. BAER, M. R. Baer, M.R. BAER, M.R. Baer, MARIA R. BAER

899

Publications

23.1K

Citations

H-Index

173

Concepts

All Affiliations

University of Maryland, Baltimore Roswell Park Comprehensive Cancer Center U-M Rogel Cancer Center University of Chicago The Ohio State University

About

Maria R. Baer is an author at University of Maryland, Baltimore specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	100	5.8K
2	Health Sciences	19	34	2.1K
3	Natural Sciences	7	7	396
4	Public Health	4	4	89
5	Education	1	1	38

Maria R. Baer

259

Publications

20.3K

Citations

H-Index

Page 1

	Year	Citations
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes, New England Journal of Medicine	2019	1.2K
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Journal of Clinical Oncology	2010	757
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole, The Lancet Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2021	721
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes, The Lancet Oncology Selective InhibitionHematological MalignancyOncologyMedicinePharmacotherapy	2017	484
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet, Journal of Clinical Oncology	2012	405
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Mark J. Levis, Farhad Ravandi, Eunice S. Wang, Blood	2011	395
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Maria R. Baer, Stephen L. George, Richard K. Dodge, Blood	2002	365
Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study Heiko Becker, Guido Marcucci, Kati Maharry, Journal of Clinical Oncology	2009	339
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461 Sherif S. Farag, Kellie J. Archer, Krzysztof Mrózek, Blood	2006	329
<i>TET2</i> Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Klaus H. Metzeler, Kati Maharry, Michael D. Radmacher, Journal of Clinical Oncology	2011	319

Page 1